Company profile
Oxford Expression Technologies Limited
Oxford Expression Technologies | World leaders in Baculovirus technology
Supporting the global pharma and biotech industries, and a world-renowned centre of excellence for Baculovirus protein expression.
Corporate ownership
Updated 06 Jun 2026 16:52
Latest accounts
Financial period: 1 Nov 2023 to 31 Oct 2024
Company events
Reference milestones and recent Companies House filing stream events.
Accounts due
Accounts DueNext accounts due date
Confirmation statement due
Confirmation DueNext confirmation statement due date
Accounts With Accounts Type Total Exemption Full
Accounts AnalysedAA | Transaction MzUxNDc2Mzk1OGFkaXF6a2N4
Published 07 Apr 2026 14:08
Confirmation statement filed
ConfirmationLast confirmation statement made up date
Accounts filed
AccountsLast accounts made up date
Confirmation Statement With Updates
Confirmation-statementCS01 | Transaction MzQ1NTc4OTA1N2FkaXF6a2N4
Published 20 Feb 2025 06:31
Termination Director Company With Name Termination Date
OfficersTM01 | Transaction MzQzNzk2Mzc2NmFkaXF6a2N4
Published 01 Oct 2024 12:54
Incorporated
InceptionCompany registered at Companies House
Public funding
Projects
CCHFv vaccine for LMICs - transition from preclinical to clinical studies
1 Dec 2023 to 31 Mar 2026
Crimean Congo Haemorrhagic Fever virus (CCHFv) is endemic in \>30 countries, almost all Low Middle Income Countries (LMICs) in Africa, the Balkans, Middle East and Asia with an estimated 3 billion people at risk. The expanding geographic range of the tick host along with trade in infected but asymptomatic livestock is fuelling the spread of CCHFv. Virus o...
Development of a subunit vaccine against CCHF virus for use in low-middle income countries; completion of pre-clinical studies
1 Apr 2022 to 31 Mar 2023
Crimean Congo Haemorrhagic Fever virus (CCHFv) is the most widespread tick-borne viral disease affecting people. It is endemic in \>30 countries, almost all of which are LMICs in Africa, the Balkans, Middle East and Central Asia with an estimated 3 billion people at risk. The expanding geographic range of the tick along with trade in infected but asymptom...
COVID 19: a rapidly scaleable SARS-CoV-2 vaccine in insect cells
1 Dec 2021 to 31 Jan 2022
The best validated approach to protect individuals against coronaviruses such as COVID-19 is to target the spike protein that surrounds the particle and which plays a key role in cellular attachment and virus cell entry. One of the safest ways to make spike protein for use in a vaccine is to use a production system based on a virus that can only grow in i...
Covid-19: a rapidly scalable SARS-Cov-2 vaccine platform based on recombinant spoke protein manufactured in insect cells using flashBAC to maximise yield and quality
1 Aug 2020 to 31 Jan 2022
The best validated approach to protect individuals against coronaviruses such as COVID-19 is to target the spike protein that surrounds the particle and which plays a key role in cellular attachment and virus cell entry. One of the safest ways to make spike protein for use in a vaccine is to use a production system based on a virus that can only grow in i...
Development of an economically viable CCHF virus vaccine
1 Feb 2018 to 31 Jan 2022
Crimean-Congo Haemorrhagic Fever (CCHF) is a serious virus (v) disease primarily transmitted to humans by ticks. The mortality rate is up to 40% with survivors experiencing long term debilitating health problems that have socio-economic impact at all levels. Incidences of the disease are increasing, with outbreaks across much of sub-Saharan Africa, large ...
Newton Fund - Pretransplant gene therapy of pancreatic islet tissue; towards a therapy for Diabetes type I in Mexico
1 Oct 2016 to 31 Dec 2018
More than 1 million people in Mexico suffer from diabetes mellitus type 1 (DM1), in which pancreatic islet cells have been damaged so that they cannot make insulin to regulate body glucose levels. Today DM1 is the most frequent metabolic disorder affecting infants and young people in Mexico. The diabetes has to be treated with life-long, daily injections ...
Development of an economically viable CCHF virus vaccine for local production
1 Sep 2016 to 31 Aug 2017
Some of the deadliest diseases we know about occur in areas of the world least well equipped to deal with them. The fact that they rarely cause problems in developed countries has hampered the production of preventative vaccines. Interest in these so called neglected diseases is limited owing to the small markets involved and poorly resourced healthcare. ...
A novel production system for virus-like particle vaccines
1 Apr 2014 to 30 Nov 2015
One of the greatest challenges to human and animal health, particularly to young adults, is the threat of emerging infectious diseases, which can spread rapidly across countries and through unprotected populations. Many of these threats come from virus diseases, in which mutations enables a virus to spread into new animal or human populations. It is there...